Filing Flows

Filing Flows › Companies › Mirum Pharmaceuticals › Cash flow

Mirum Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.6M in Q3 2026 · −$274M over twelve months

Operating cash flow−$4.3M
Capital spending−$1.3M
Free cash flow−$5.6M

Analysis

In Q3 2026, Mirum Pharmaceuticals generated −$4.3M of operating cash flow and spent $1.3M on capital projects, leaving free cash flow of −$5.6M. That is $45.1M less than in Q3 2025 ($39.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$271M; the largest uses were operating cash flow ($271M), other investing ($197M), capital spending ($2.6M); besides operations, cash came from other financing ($396M), shares issued ($40.3M); the cash balance fell by $37.6M.

Operating cash flow was −$4.3M against net income of −$40.8M. The largest differences: stock-based pay +$33.3M, receivables −$13.1M, depreciation & amortization +$6.9M.

Free cash flow

Mirum Pharmaceuticals: free cash flow by quarterMirum Pharmaceuticals: free cash flow by quarter−$5.1MQ4 2024−$2.0MQ1 2025$11.9MQ2 2025$39.5MQ3 2025$5.5MQ4 2025−$229MQ1 2026−$44.3MQ2 2026−$5.6MQ3 2026
Operating cash flow less capital spending.
Mirum Pharmaceuticals: operating cash flow against capital spendingMirum Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$5.1M$20KQ4 2024−$2.0M$41KQ1 2025$12.0M$126KQ2 2025$39.7M$187KQ3 2025$6.1M$600KQ4 2025−$229M$664KQ1 2026−$44.3M$23KQ2 2026−$4.3M$1.3MQ3 2026
Latest (Q3 2026): Operating cash flow −$4.3M, Capital spending $1.3M.

Capital allocation, year by year

Mirum Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearMirum Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$133MFY2021: Shares issued $2.1MFY2021: Capital spending −$24K$2.1MFY2021FY2022: Operating cash flow −$120MFY2022: Shares issued $28.6MFY2022: Capital spending −$278K$28.6MFY2022FY2023: Operating cash flow −$70.9MFY2023: Net borrowing $305MFY2023: Shares issued $24.9MFY2023: Capital spending −$109KFY2023: Acquisitions −$213M$330MFY2023FY2024: Operating cash flow $10.3MFY2024: Shares issued $17.7MFY2024: Capital spending −$993K$28.0MFY2024FY2025: Operating cash flow $55.8MFY2025: Shares issued $40.1MFY2025: Capital spending −$954K$96.0MFY2025
Over these 5 years operating cash flow totalled −$258M; the largest uses were operating cash flow ($324M) and acquisitions ($213M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$374M
Debtnone
Net cash$374M
Cash runway16 months

Mirum Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$274M a year at the current rate against $374M of cash and investments: a runway of about 16 months before any new financing.

Where the cash came from and went

Mirum Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Mirum Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$87.5MNet borrowing (+) / repaid (−)−$62.1MOther investing−$27.6MShares issued$7.8MOperating cash flow−$4.3MCapital spending−$1.3MExchange rates−$17K
Mirum Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Mirum Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$396MOperating cash flow−$271MOther investing−$197MShares issued$40.3MCash drawn (+) / kept (−)$37.6MExchange rates−$3.1MCapital spending−$2.6M

From profit to cash

Mirum Pharmaceuticals: net income to operating cash flow, Q3 2026Mirum Pharmaceuticals: net income to operating cash flow, Q3 2026Net income−$40.8MDepreciation & amortization$6.9MStock-based pay$33.3MOther non-cash−$352KReceivables−$13.1MInventory−$889KPrepaid and other assets−$4.3MOperating cash flow−$4.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$4.3M−$1.3M−$62.1M$7.8M$87.5M−$5.6M
Q2 2026−$44.3M−$23K—$13.4M−$5.8M−$44.3M
Q1 2026−$229M−$664K—$10.1M−$28.5M−$229M
Q4 2025$6.1M−$600K—$9.0M−$15.7M$5.5M
Q3 2025$39.7M−$187K—$16.1M−$53.9M$39.5M
Q2 2025$12.0M−$126K—$8.7M−$16.4M$11.9M
Q1 2025−$2.0M−$41K—$6.4M$10.7M−$2.0M
Q4 2024−$5.1M−$20K—$5.3M$466K−$5.1M

Mirum Pharmaceuticals: income statement and cash flow

Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%. The chart follows the revenue to costs, profit and cash.

Mirum Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.